The FDA did grant Neuralink an expanded Investigational Device Exemption (IDE) for its N2 implant in January 2026, allowing trials with up to 30 patients. However, this is an expanded clinical trial approval, not commercial deployment approval. The 'robotic limb control by next year' claim conflates research milestones with clinical availability. Current Neuralink trials focus on cursor control and text input, not robotic limb manipulation.